NASHUA, N.H., July 7 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that the Company’s second quarter 2008 financial results will be announced before market open on Thursday, July 31, 2008. iCAD management will discuss the results during a conference call scheduled for 10:00 a.m. ET that same morning.
Shareholders and other interested parties may participate in the conference call by dialing +1-866-356-4281 (domestic) or +1-617-597-5395 (international) and entering passcode 59209440 a few minutes before 10:00 a.m. ET on Thursday, July 31, 2008. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.icadmed.com.
A replay of the conference call will be accessible two hours after its completion through August 7, 2008 by dialing +1-888-286-8010 (domestic) or +1-617-801-6888 (international) and entering passcode 43767917. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over 2,200 women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn &
Associates at 212-838-3777 x6604 or via email at afields@lhai.com
For iCAD Public Relations, contact Jill Testagrossa of Schwartz Communications
at 781-684-0770 or via email at icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
CONTACT: Darlene Deptula-Hicks, EVP and CFO of iCAD, +1-603-882-5200, ext.
7944, ddeptula@icadmed.com; For iCAD Investor Relations, Anne Marie Fields
of Lippert-Heilshorn & Associates, +1-212-838-3777, ext. 6604,
afields@lhai.com; For iCAD Public Relations, Jill Testagrossa of Schwartz
Communications, +1-781-684-0770, icad@schwartz-pr.com
Web site: http://www.icadmed.com/
